Apotex Rolls Out Pegfilgrastim A Year After Canadian Approval
Apotex is rolling out its Lapelga pegfilgrastim biosimilar across Canada, almost a year after securing marketing authorization. But Mylan is seeking local reimbursement for its Fulphila alternative.
You may also be interested in...
Following recent Health Canada approval, Apotex has launched partner mAbxience’s Bambevi (bevacizumab) biosimilar across Canada, adding to its portfolio of biosimilars that includes both filgrastim and pegfilgrastim.
Apotex has received Health Canada approval for its Bambevi bevacizumab rival to Avastin, with the firm citing the nod as a first for its Apobiologix division.
Sandoz Canada is looking to bolster its portfolio of biosimilars after obtaining marketing authorizations for both pegfilgrastim and rituximab.